1 Markwart, F., “The development of hirudin as an anti-thrombotic drug”, Thromb. Res., 74, 1—23(1994). 2 Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode, W., Huber, R., Roitsch, C., Fenton, J.W., “The structure of a complex of recombinant hirudin and human α-thrombin”, Science, 249, 277—280(1990). 3 Rydel, T.J., Tulinsky, A., Bode, W., Huber, R., “Refined structure of the hirudin -thrombin complex”, J. Mol. Biol., 221, 583—601(1991). 4 Markwardt, F., “Past, present and future of hirudin”, Haemost. 21(Suppl. 1), 11— 26(1991). 5 Ulbricht, K., Bucha, E., Poschel, KA., Stein, G., Wolf, G., Nowak, G., “The use of PEG-Hirudin in chronic hemodi-alysis monitored by the Ecarin Clotting Time: Influence on clotting of the extracorporeal system and hemostatic parameters”, Clin. Nephrol., 65(3), 180—190(2006). 6 Alexander, B., Burnand, K.G., Lattimer, C.L., Humphries, J., Gaffney, P.J., Eastham, D., Smith, A., “The effect of anticoagulation with subcutaneously delivered polyeth-ylene glycol conjugated hirudin and recombinant tissue plasminogen activator on recurrent stenosis in the rabbit double-balloon injury model”, Thromb. Res., 113(2), 155 —161(2004). 7 Poschel, K.A., Bucha, E., Esslinger, H.U., Ulbricht, K., Nortersheuser, P., Stein, G., Nowak, G., “Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis”, Kidney Int., 65(2), 666—674(2004). 8 Roberts, M.J., Bentley, M.D., Harris, J.M., “Chemistry for peptide and protein PEGylation”, Adv. Drug. Deliv. Rev., 54, 459—476(2002). 9 Veronese, F., “Peptide and protein PEGylation: A review of problems and solutions ”, Biomater., 22, 405—417(2001). 10 Monkarsh, S.P., Ma, Y., Aglione, A., Bailon, P., Ciolek, D., DeBarbieri, B., Graves, M.C., Hollfelder, K., Michel, H., Palleroni, A., Porter, J.E., Russoman, E., Roy, S., Pan, Y.E., “Positional isomers of monopegylated interferon a-2a: Isolation, characterization, and biological activity”, Anal. Biochem., 247, 434—440(1997). 11 Uchio, T., Baudys, M., Liu, F., Song, S.C., Kim, S.W., “Site-specific insulin conjugates with enhanced stability and extended action profile”, Adv. Drug. Deliv. Rev., 35, 289—306(1999). 12 Kinstler, O.B., Gabriel, N.E., Farrar, C.E., DePrince, R.B., “N-terminally chemically modified protein compo-sition methods”, US Pat., 5985265 (1999). 13 Goffin, V., Bernichtein, S., Carriere, O., Bennett, W.F., Kopchick, J.J., Kelly, P.A., “The human growth hormone antagonist B2036 does not interact with the prolactin re- ceptor”, Endocrinol., 140, 3853—3856(1999). 14 Giardino, R., Capelli, S., Fini, M., Giavaresi, G., Orienti, L., Veronese, F.M., Caliceti, P., Rocca, M., “Biopolymeric modification of superoxide dismutase (mPEG-SOD) to prevent muscular ischemia-reperfusion damage”, Int. J. Artif. Organs., 18, 167—172(1995). 15 Esslinger, H.U., Haas, S., Mauer, R., Lassmann, A., Dubbers, K., Muler-Pelzer, H., “Pharmacolodynamic and safety results of PEG-hirudin in healthy volunteers”, Thromb. Haemost., 5, 911—919(1997). 16 Li, W.J., Lin, B.C., Su, Z.G., “Analytical methods for PEGylated protein drugs”, Analysis, 29, 228—231(2001). (in Chinese) 17 Mcgoff, P., Baziotis, A.C., Maskiewicz, R., “Analysis of polyethylene glycol modified superoxidedismutase by chromatographic, electrophoretic, light scattering, chemical and enzymatic methods”, Chem. Pharm. Bull., 36, 3079—3091(1988). 18 Biscoff, R., “Polyethylene glycol-hirudin conjugates, process for preparing them and their use for the treatment of thromboses”, U.S. Pat., 5362858(1994). 19 Snyder, S.L., Sobocinski, P.Z., “An improved 2,4,6-trinitrobenzenesulfonic acid method for determina-tion of amines”, Anal. Biochem., 64, 284—288(1975). 20 Manfred, M.K., “Detection and molecular weight deter-mination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis”, Anal. Biochem., 200, 244—248(1992). 21 Bullock, J., Chowdhury, S., Severdia, A., Sweeney, J., Johnston, D., Pachla, L., “ Comparison of results of vari-ous methods used to determine the extent of modification of methoxy polyethylene glycol 5000-modified bovine cupri-zinc superoxide dismutase”, Anal. Biochem., 254, 254—262(1997).
|